Article
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
- Author:
- Edited Jame Abraham
Publish date: February 19, 2018
Article
Uridine triacetate provides antidote for 5-fluorouracil overdose and toxicity
- Author:
- Edited Jame Abraham
Publish date: August 24, 2016
Article
Trabectedin expands treatment options for some forms of advanced soft tissue sarcoma
- Author:
- Edited Jame Abraham
Publish date: May 23, 2016
Article
More success for immunotherapy with nivolumab approval for metastatic RCC
- Author:
- Edited Jame Abraham
Publish date: April 27, 2016
Article
Encapsulated irinotecan provides novel option for hard-to-treat pancreatic cancer
- Author:
- Edited Jame Abraham
Publish date: March 25, 2016
Article
Second targeted combination regime approved for metastatic melanoma
- Author:
- Edited Jame Abraham
Publish date: February 21, 2016
Article
Idarucizumab given the nod as the first specific antidote for an oral anticoagulant
- Author:
- Edited Jame Abraham
Publish date: January 26, 2016
Article
Filgrastim-sndz debuts as the first biosimilar approved in United States
- Author:
- Edited Jame Abraham
Publish date: December 14, 2015
Article
Approval reinstates gefitinib as a therapy for lung cancer
- Author:
- Edited Jame Abraham
Publish date: November 16, 2015
Article
Dinutuximab combination therapy becomes first approval for high-risk neuroblastoma
- Author:
- Edited Jame Abraham
Publish date: October 19, 2015
Article
Nivolumab: first immunotherapy approved for lung cancer
- Author:
- Edited Jame Abraham
Publish date: September 23, 2015
Article
Olaparib for BRCA-mutated advanced ovarian cancer
- Author:
- Edited Jame Abraham
Publish date: June 23, 2015
Article
Blinatumomab for hard-to-treat form of acute lymphoblastic leukemia
- Author:
- Edited Jame Abraham
Publish date: May 13, 2015
Article
Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
- Author:
- Edited Jame Abraham
Publish date: March 16, 2015
Article
Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
- Author:
- Edited Jame Abraham
Publish date: December 17, 2014